Picture of Biodesix logo

BDSX Biodesix Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Annual income statement for Biodesix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K
Standards:
USG
USG
USG
USG
Status:FinalFinalFinalFinal
Revenue
Total Revenue20.424.645.654.5
Cost of Revenue
Gross Profit1618.523.624
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses44.151.368.593.1
Operating Profit-23.7-26.7-22.9-38.6
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-26.2-30.7-31.4-43.2
Net Income After Taxes-26.2-30.7-31.4-43.2
Net Income Before Extraordinary Items
Net Income-26.2-30.7-31.4-43.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-26.2-30.7-31.4-43.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.93-1.04-1.15-1.66
Dividends per Share

Or unlock with your email

Or unlock with your email